Abstract
The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Cells, Cultured
-
Drug Delivery Systems
-
Flow Cytometry
-
Humans
-
Indicators and Reagents
-
Mice
-
Mice, Inbred BALB C
-
Microscopy, Fluorescence
-
Neovascularization, Pathologic / therapy*
-
Oligopeptides / administration & dosage
-
Oligopeptides / chemistry
-
Peptides / chemistry
-
Phosphatidylethanolamines / chemistry
-
Polyethylene Glycols
-
RNA, Small Interfering / administration & dosage*
-
RNA, Small Interfering / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
Indicators and Reagents
-
Oligopeptides
-
Peptides
-
Phosphatidylethanolamines
-
RNA, Small Interfering
-
dioleoyl phosphatidylethanolamine
-
Polyethylene Glycols
-
arginyl-glycyl-aspartic acid